Periostin in intrahepatic cholangiocarcinoma: Pathobiological insights and clinical implications

Experimental and Molecular Pathology

Volumn 97, Issue 3, 2014, Pages 515-524

  Sirica, Alphonse E ^a   Almenara, Jorge A ^a   Li, Chao ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Akt; Cancer associated fibroblasts; Cholangiocarcinoma cell migration and invasion; Integrins; Metastasis; Periostin; Tumor desmoplasia

Indexed keywords

BIOLOGICAL MARKER; CELL SURFACE RECEPTOR; COLLAGEN TYPE 1; FOCAL ADHESION KINASE; GLYCOPROTEIN; INTEGRIN; PROTEIN KINASE B; TENASCIN; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA; CELL ADHESION MOLECULE; POSTN PROTEIN, HUMAN;

BILE DUCT CARCINOMA; CANCER CELL; CANCER GROWTH; CANCER PATIENT; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER THERAPY; CELL GROWTH; DRUG TARGETING; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; FIBROBLAST; FIBROGENESIS; HUMAN; METASTASIS; NONHUMAN; PANCREAS ADENOCARCINOMA; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; REVIEW; SIGNAL TRANSDUCTION; STROMA; TUMOR INVASION; BILE DUCT TUMOR; INTRAHEPATIC BILE DUCT; METABOLISM; PATHOLOGY;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CELL ADHESION MOLECULES; CHOLANGIOCARCINOMA; HUMANS;

EID: 84909995740     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2014.10.007     Document Type: Review

References (89)

1. Allen M., Louse Jones J. Jekyll and Hyde: the role of the microenvironment on the progression of cancer. J. Pathol. 2011, 223:162-176.
2. Bao S., Ouyang G., Bai X., Huang Z., Ma C., Liu M., et al. Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell 2004, 5:329-339.
3. Baril P., Gangeswaran R., Mahon P.C., Caulee K., Kocher H.M., Harada T., et al. Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the β4 integrin and the PI3K pathway. Oncogene 2007, 26:2082-2094.
4. Ben Q.-W., Zhao Z., Ge S.-F., Zhou J., Yuan F., Yuan Y.-Z. Circulating levels of periostin may help identify patients with more aggressive colorectal cancer. Int. J. Oncol. 2009, 34:821-828.
5. Ben Q.-W., Jin X.-L., Liu J., Cai X., Yuan F., Yuan Y.-Z. Periostin, a matrix specific protein, is associated with proliferation and invasion of pancreatic cancer. Oncol. Rep. 2011, 25:709-716.
6. Bertotti A., Comoglio P.M., Trusolino L. β4 integrin is a transforming molecule that unleashes Met tyrosine kinase tumorigenesis. Cancer Res. 2005, 65:10674-10679.
7. Bierie B., Moses H.L. Tumor microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat. Rev. Cancer 2006, 6:506-520.
8. Campbell D.J.W., Dumur C.I., Lamour N.F., DeWitt J.L., Sirica A.E. Novel organotypic culture model of cholangiocarcinoma progression. Hepatol. Res. 2012, 42:1119-1130.
9. Chuaysri C., Thuwajit P., Paupairoj A., Chau-In S., Suthiphongchai T., Thuwajit C. Alpha-smooth muscle actin-positive fibroblasts promote biliary cell proliferation and correlate with poor survival in cholangiocarcinoma. Oncol. Rep. 2009, 21:957-969.
10. Chung C.Y., Erickson H.P. Glycosaminoglycans modulate fibronectin matrix assembly and are essential for matrix incorporation of tenascin-C. J. Cell Sci. 1997, 110:1413-1419.
11. Coutu D.L., Wu J.H., Monette A., Rivard G.-É., Blostein M.D., Galipeau J. Periostin, a member of a novel family of vitamin K-dependent proteins, is expressed by mesenchymal stromal cells. J. Biol. Chem. 2008, 283:17991-18001.
12. Darby I.A., Vuillier-Devillers K., Pinault É., Sarrazy V., Lepreux S., Balabaud C., et al. Proteomic analysis of differentially expressed proteins in peripheral cholangiocarcinoma. Cancer Microenviron. 2010, 4:73-91.
13. Dodson R.M., Weiss M.J., Cosgrove D., Herman J.M., Kamel I., Anders R., et al. Intrahepatic cholangiocarcinoma: management options and emerging therapies. J. Am. Coll. Surg. 2013, 217:736-750.e4.
14. Dumur C.I., Campbell D.J.W., DeWitt J.L., Oyesanya R.A., Sirica A.E. Differential gene expression profiling of cultured neu-transformed versus spontaneously-transformed rat cholangiocytes and of corresponding cholangiocarcinomas. Exp. Mol. Pathol. 2010, 89:227-235.
15. Elliott C.G., Wang J., Guo X., Xu S.-W., Eastwood M., Guan J., et al. Periostin modulates myofibroblast differentiation during full-thickness cutaneous wound repair. J. Cell Sci. 2012, 125:121-132.
16. Erkan M., Kleeff J., Gorbachevski A., Reiser C., Mitkus T., Esposito I., et al. Periostin creates a tumor-supportive microenvironment in the pancreas by sustaining fibrogenic stellate cell activity. Gastroenterology 2007, 132:1447-1464.
17. Erkan M., Reiser-Erkan C., Michalski C.W., Deucker S., Sauliunaite D., Streit S., et al. Cancer-stellate cell interactions perpetuate the hypoxia-fibrosis cycle in pancreatic ductal adenocarcinoma. Neoplasia 2009, 11:497-508.
18. Fonseca N.A., Gregório A.C., Valério-Fernandes A., Simões S., Moreira J.N. Bridging cancer biology and the patient's needs with nanotechnology-based approaches. Cancer Treat. Rev. 2014, (Epub 2014 Feb 22).
19. Frangogiannis N.G. Matricellular proteins in cardiac adaptation and disease. Physiol. Rev. 2012, 92:635-688.
20. Fujimoto K., Kawaguchi T., Nakashima O., Ono J., Ohta S., Kawaguchi A., et al. Periostin, a matrix protein, has potential as a novel serodiagnostic marker for cholangiocarcinoma. Oncol. Rep. 2011, 25:1211-1216.
21. Fukushima N., Kikuchi Y., Nishiyama T., Kudo A., Fukayama M. Periostin deposition in the stroma of invasive and intraductal neoplasms of the pancreas. Mod. Pathol. 2008, 21:1044-1053.
22. Guo W., Pylayeva Y., Pepe A., Yoshioka T., Muller W.J., Inghirami G., et al. β4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. Cell 2006, 126:489-502.
23. Hamilton D.W. Functional role of periostin in development and wound repair: implications for connective tissue disease. J. Cell Commun. Signal. 2008, 2:9-17.
24. Hoersch S., Andrade-Navarro M.A. Periostin shows increased evolutionary plasticity in its alternatively spliced region. BMC Evol. Biol. 2010, 10:30.
25. Horiuchi K., Amizuka N., Takeshita S., Takamatsu H., Katsuura M., Ozawa H., et al. Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor beta. J. Bone Miner. Res. 1999, 14:1239-1249.
26. Ishikawa K., Yoshida S., Nakao S., Nakama T., Kita T., Asato R., et al. Periostin promotes the generation of fibrous membranes in proliferative vitreoretinopathy. FASEB J. 2014, 28:131-142.
27. Isono T., Kim C.J., Ando Y., Sakurai H., Okada Y., Inoue H. Suppression of cell invasiveness by periostin via TAB1/TAK1. Int. J. Oncol. 2009, 35:425-432.
28. Izuhara K., Arima K., Ohta S., Suzuki S., Inamitsu M., Yamamoto K. Periostin in allergic inflammation. Allergol. Int. 2014, 63:143-151.
29. Kii I., Nishiyama T., Li M., Matsumoto K., Saito M., Amizuka N., et al. Incorporation of tenascin-C into the extracellular matrix by periostin underlies an extracellular meshwork architecture. J. Biol. Chem. 2010, 285:2028-2039.
30. Kim C.J., Isono T., Tambe Y., Chano T., Okabe H., Okada Y., et al. Role of alternative splicing of periostin in human bladder carcinogenesis. Int. J. Oncol. 2008, 32:161-169.
31. Kudo A. Periostin in fibrillogenesis for tissue regeneration: periostin actions inside and outside the cell. Cell. Mol. Life Sci. 2011, 68:3201-3207.
32. Kudo Y., Siriwardena B.S.M.S., Hatano H., Ogawa I., Takata T. Periostin: novel diagnostic and therapeutic target for cancer. Histol. Histopathol. 2007, 22:1167-1174.
33. Kyutoku M., Taniyama Y., Katsuragi N., Shimizu H., Kunugiza Y., Iekushi K., et al. Role of periostin in cancer progression and metastasis: inhibition of breast cancer progression and metastasis by anti-periostin antibody in a murine model. Int. J. Mol. Med. 2011, 28:181-186.
34. Lee Y.J., Kim I.S., Park S.-A., Kim Y., Lee J.E., Noh D.-Y., et al. Periostin-binding DNA aptamer inhibits breast cancer growth and metastasis. Mol. Ther. 2013, 21:1004-1013.
35. Li G., Jin R., Norris R.A., Zhang L., Yu S., Wu F., et al. Periostin mediates vascular smooth muscle cell migration through the integrins ανβ3 and ανβ5 and focal adhesion kinase (FAK) pathway. Atherosclerosis 2010, 208:358-365.
36. Li L., Fan D., Wang C., Wang J.-Y., Cui X.-B., Wu D., et al. Angiotensin II increases periostin expression via Ras/p38 MAPK/CREB and ERK1/2/TGF-β1 pathways in cardiac fibroblasts. Cardiovasc. Res. 2011, 91:80-89.
37. Li M., Li C., Li D., Xie Y., Shi J., Li G., et al. Periostin, a stroma-associated protein, correlates with tumor invasiveness and progression in nasopharyngeal carcinoma. Clin. Exp. Metastasis 2012, 29:865-877.
38. Li Y.-S., Ni S.-Y., Meng Y., Shi X.-L., Zhao X.-W., Luo H.-H., et al. Angiotensin II facilitates fibrogenic effect of TGF-β1 through enhancing the down-regulation of BAMBI caused by LPS: a new pro-fibrotic mechanism of angiotensin II. PLoS One 2013, 8:e76289.
39. Litvin J., Zhu S., Norris R., Markwald R. Periostin family of proteins: therapeutic targets for heart disease. Anat. Rec. 2005, 287A:1205-1212.
40. Luo J.-H., Zhou J., Gao Y. Correlation between periostin and SNCG and esophageal cancer invasion, infiltration and apoptosis. Asian Pac. J. Trop. Med. 2013, 6:516-519.
41. Lv Y., Wang W., Jia W.-D., Sun Q.-K., Li J.-S., Ma J.-L., et al. High-level expression of periostin is closely related to metastatic potential and poor prognosis of hepatocellular carcinoma. Med. Oncol. 2013, 30:385.
42. Lv Y., Wang W., Jia W.D., Sun Q.K., Huang M., Zhou H.C., et al. High preoperative levels of serum periostin are associated with poor prognosis in patients with hepatocellular carcinoma after hepatectomy. Eur. J. Surg. Oncol. 2013, 39:1129-1135.
43. Mael-Ainin M., Abed A., Conway S.J., Dussaule J.-C., Chatziantoniou C. Inhibition of periostin expression protects against the development of renal inflammation and fibrosis. J. Am. Soc. Nephrol. 2014, 25:1724-1736.
44. Malanchi I., Santamaria-Martínez A., Susanto E., Peng H., Lehr H.-A., Delaloye J.-F., et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 2012, 481:85-89.
45. Maruhashi T., Kii I., Saito M., Kudo A. Interaction between periostin and BMP-1 promotes proteolytic activation of lysyl oxidase. J. Biol. Chem. 2010, 285:13294-13303.
46. Mertens J.C., Fingas C.D., Christensen J.D., Smoot R.L., Bronk S.F., Werneburg N.W., et al. Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma. Cancer Res. 2012, 73:897-907.
47. Michaylira C.Z., Wong G.S., Miller C.G., Gutierrez C.M., Nakagawa H., Hammond R., et al. Periostin, a cell adhesion molecule, facilitates invasion in the tumor microenvironment and annotates a novel tumor-invasive signature in esophageal cancer. Cancer Res. 2010, 70:5281-5292.
48. Morra L., Moch H. Periostin expression and epithelial-mesenchymal transition in cancer: a review and an update. Virchows Arch. 2011, 459:465-475.
49. Morra L., Rechsteiner M., Casagrande S., von Teichman A., Schraml P., Moch H., et al. Characterization of periostin isoform pattern in non-small cell lung cancer. Lung Cancer 2012, 76:183-190.
50. Naik P.K., Bozyk P.D., Bentley J.K., Popova A.P., Birch C.M., Wilke C.A., et al. Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 2012, 303:L1046-L1056.
51. Norris R.A., Moreno-Rodriguez R., Hoffman S., Markwald R.R. The many facets of the matricellular protein periostin during cardiac development, remodeling, and pathophysiology. J. Cell Commun. Signal. 2009, 3:275-286.
52. Nuzzo P.V., Rubagotti A., Zinoli L., Ricci F., Salvi S., Boccardo S., et al. Prognostic value of stromal and epithelial periostin expression in human prostate cancer: correlation with clinical pathological features and the risk of biochemical relapse or death. BMC Cancer 2012, 12:625.
53. Okabe H., Beppu T., Hayashi H., Horino K., Masuda T., Komori H., et al. Hepatic stellate cells may relate to progression of intrahepatic cholangiocarcinoma. Ann. Surg. Oncol. 2009, 16:2555-2564.
54. Okamoto K., Tajima H., Ohta T., Nakanuma S., Hayashi H., Nakagawara H., et al. Angiotensin II induces tumor progression and fibrosis in intrahepatic cholangiocarcinoma through an interaction with hepatic stellate cells. Int. J. Oncol. 2010, 37:1251-1259.
55. Okamoto K., Tajima H., Nakanuma S., Sakai S., Makino I., Kinoshita J., et al. Angiotensin II enhances epithelial-to-mesenchymal transition through the interaction between activated hepatic stellate cells and the stromal cell-derived factor-1/CXCR4 axis in intrahepatic cholangiocarcinoma. Int. J. Oncol. 2012, 41:573-582.
56. Olive K.P., Jacobetz M.A., Davidson C.J., Gopinathan A., McIntyre D., Honess D., et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 12:1457-1461.
57. Ontsuka K., Kotobuki Y., Shiraishi H., Serada S., Ohta S., Tanemura A., et al. Periostin, a matricellular protein, accelerates cutaneous wound repair by activating dermal fibroblasts. Exp. Dermatol. 2012, 21:331-336.
58. Oskarsson T., Massagué J. Extracellular matrix players in metastatic niches. EMBO J. 2012, 31:254-256.
59. Ouyang G., Liu M., Ruan K., Song G., Mao Y., Bao S. Upregulated expression of periostin by hypoxia in non-small-cell lung cancer cells promotes cell survival via the Akt/PKB pathway. Cancer Lett. 2009, 281:213-219.
60. Pratap J., Lian J.B., Javed A., Barnes G.L., van Wijnen A.J., Stein J.L., et al. Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone. Cancer Metastasis Rev. 2006, 25:589-600.
61. Razumilava N., Gores G.J. Cholangiocarcinoma. Lancet 2014, 383:2168-2179.
62. Razumilava N., Gradilone S.A., Smoot R.L., Mertens J.C., Bronk S.F., Sirica A.E., et al. Non-canonical Hedgehog signaling contributes to chemotaxis in cholangiocarcinoma. J. Hepatol. 2014, 60:599-605.
63. Rhim A.D., Oberstein P.E., Thomas D.H., Mirek E.T., Palermo C.F., Sastra S.A., et al. Stromal elements act to restrain, rather than support pancreatic ductal carcinoma. Cancer Cell 2014, 25:735-747.
64. Riener M.-O., Fritzsche F.R., Soll C., Pestalozzi B.C., Probst-Hensch N., Clavien P.-A., et al. Expression of the extracellular matrix protein periostin in liver tumours and bile duct carcinomas. Histopathology 2010, 56:600-606.
65. Ruan K., Bao S., Ouyang G. The multifaceted role of periostin in tumorigenesis. Cell. Mol. Life Sci. 2009, 66:2219-2230.
66. Ruys A.T., Koerkamp B.G., Wiggers J.K., Klümpen H.-J., ten Kate F.J., van Gulik T.M. Prognostic biomarkers in patients with resected cholangiocarcinoma: a systematic review and meta-analysis. Ann. Surg. Oncol. 2014, 21:487-500.
67. Sheu A.Y., Zhang Z., Omary R.A., Larson A.C. Invasive catheterization of the hepatic artery for preclinical investigation of liver-directed therapies in rodent models of liver cancer. Am. J. Transl. Res. 2013, 5:269-278.
68. Sia D., Tovar V., Moeini A., Llovet J.M. Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. Oncogene 2013, 32:4861-4870.
69. Sirica A.E. The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma. Nat. Rev. Gastroenterol. Hepatol. 2012, 9:44-54.
70. Sirica A.E., Gores G.J. Desmoplastic stroma and cholangiocarcinoma: clinical implications and therapeutic targeting. Hepatology 2014, 59:2397-2402.
71. Sirica A.E., Zhang Z., Lai G.-H., Asano T., Shen X.-N., Ward D.J., et al. A novel "patient-like" model of cholangiocarcinoma progression based on bile duct inoculation of tumorigenic rat cholangiocyte cell lines. Hepatology 2008, 47:1178-1190.
72. Sirica A.E., Dumur C.I., Campbell D.J.W., Almenara J.A., Ogunwobi O.O., DeWitt J.L. Intrahepatic cholangiocarcinoma progression: prognostic factors and basic mechanisms. Clin. Gastroenterol. Hepatol. 2009, 7:S68-S78.
73. Sun C., Zhao X., Xu K., Gong J., Liu W., Ding W., et al. Periostin: a promising target of therapeutic intervention for prostate cancer. J. Transl. Med. 2011, 9:99.
74. Takeshita S., Kikuno R., Tezuka K., Amann E. Osteoblast-specific factor 2: cloning of a putative bone adhesion protein with homology with the insect protein fasciclin I. Biochem. J. 1993, 294:271-278.
75. Thirunavukkarasu K., Mahajan M., McLarren K.W., Stifani S., Karsenty G. Two domains unique to osteoblast-specific transcription factor Osf2/Cbfa1 contribute to its transactivation function and its inability to heterodimerize with Cbfβ. Mol. Cell. Biol. 1998, 18:4197-4208.
76. Utispan K., Thuwajit P., Abiko Y., Charngkaew K., Paupairoj A., Chau-in S., et al. Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker. Mol. Cancer 2010, 9:13.
77. Utispan K., Sonongbua J., Thuwajit P., Chau-In S., Pairojkul C., Wongkham S., et al. Periostin activates integrin α5β1 through a PI3K/AKT-dependent pathway in invasion of cholangiocarcinoma. Int. J. Oncol. 2012, 41:1110-1118.
78. Wang X., Liu J., Wang Z., Huang Y., Liu W., Zhu X., et al. Periostin contributes to the acquisition of multipotent stem cell-like properties in human mammary epithelial cells and breast cancer cells. PLoS One 2013, 8:e72962.
79. Wang W., Sun Q.-K., He Y.-F., Ma D.-C., Xie M.-R., Ji C.-S., et al. Overexpression of periostin is significantly correlated to the tumor angiogenesis and poor prognosis in patients with esophageal squamous cell carcinoma. Int. J. Clin. Exp. Pathol. 2014, 7:593-601.
80. Williford J.M., Wu J., Ren Y., Archang M.M., Leong K.W., Mao H.Q. Recent advances in nanoparticle-mediated siRNA delivery. Annu. Rev. Biomed. Eng. 2014, (Epub 2014 Jun 2).
81. Wong G.S., Rustgi A.K. Matricellular proteins: priming the tumour microenvironment for cancer development and metastasis. Br. J. Cancer 2013, 108:755-761.
82. Wong G.S., Lee J.-S., Park Y.-Y., Klein-Szanto A.J., Waldron T.J., Cukierman E., et al. Periostin cooperates with mutant p53 to mediate invasion through the induction of STAT1 signaling in the esophageal tumor microenvironment. Oncogenesis 2013, 2:e59.
83. Wong G.S., Habibollahi P., Heidari P., Lee J.-S., Klein-Szanto A.J., Waldron T.J., et al. Optical imaging of periostin enables early endoscopic detection and characterization of esophageal cancer in mice. Gastroenterology 2013, 144:294-297.
84. Wu G., Wang X., Xhang X. Clinical implications of periostin in the liver metastasis of colorectal cancer. Cancer Biother. Radiopharm. 2013, 28:298-302.
85. Yang L., Serada S., Fujimoto M., Terao M., Kotobuki Y., Kitaba S., et al. Periostin facilitates skin sclerosis via PI3K/Ak mechanism in a mouse model of scleroderma. PLoS One 2012, 7:e41994.
86. Yoshioka T., Otero J., Chen Y., Kim Y.-M., Koutcher J.A., Satagopan J., et al. β4 integrin signaling induces expansion of prostate tumor progenitors. J. Clin. Invest. 2013, 123:682-699.
87. Zhu M., Fejzo M.S., Anderson L., Dering J., Ginther C., Ramos L., et al. Periostin promotes ovarian cancer angiogenesis and metastasis. Gynecol. Oncol. 2010, 119:337-344.
88. Zhu M., Saxton R.E., Ramos L., Chang D.D., Karlan B.Y., Gasson J.C., et al. Neutralizing monoclonal antibody to periostin inhibits ovarian tumor growth and metastasis. Mol. Cancer Ther. 2011, 10:1500-1508.
89. Zinn P.O., Majadan B., Sathyan P., Singh S.K., Majumder S., Jolesz F.A., et al. Radiogenomic mapping of edema/cellular invasion MRI-phenotypes in glioblastoma multiforme. Plos One 2011, 6:e25451.